Literature DB >> 9843749

Pancreastatin inhibits insulin action in rat adipocytes.

V Sánchez-Margalet1, C González-Yanes.   

Abstract

Pancreastatin (PST), a regulatory peptide with a general inhibitory effect on secretion, is derived from chromogranin A, a glycoprotein present throughout the neuroendocrine system. We have previously demonstrated the counterregulatory role of PST on insulin action in rat hepatocytes. Here, we are reporting the PST effects on rat adipocytes. PST dose dependently inhibits basal and insulin-stimulated glucose transport, lactate production, and lipogenesis, impairing the main metabolic actions of insulin in adipocytes. These effects were observed in a wide range of insulin concentrations, leading to a shift to the right in the dose-response curve. Maximal effect was observed at 10 nM PST, and the IC50 value was approximately 1 nM. Moreover, PST has a lipolytic effect in rat adipocytes (ED50 0.1 nM), although it was completely inhibited by insulin. In contrast, PST dose dependently stimulated protein synthesis and enhanced insulin-stimulated protein synthesis. In summary, these data show the lipokinetic effect of PST and the inhibitory effect of PST on insulin metabolic action within a range of physiological concentrations. Therefore, these results give new pathophysiological basis for the association of PST with insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843749     DOI: 10.1152/ajpendo.1998.275.6.E1055

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

2.  Widdrol-induced lipolysis is mediated by PKC and MEK/ERK in 3T3-L1 adipocytes.

Authors:  Hyun Young Jeong; Hee Jung Yun; Byung Woo Kim; Eun Woo Lee; Hyun Ju Kwon
Journal:  Mol Cell Biochem       Date:  2015-09-10       Impact factor: 3.396

3.  A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis.

Authors:  Jiaur R Gayen; Maziyar Saberi; Simon Schenk; Nilima Biswas; Sucheta M Vaingankar; Wai W Cheung; Sonia M Najjar; Daniel T O'Connor; Gautam Bandyopadhyay; Sushil K Mahata
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

Review 4.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism.

Authors:  Nilima Biswas; Ryan S Friese; Jiaur R Gayen; Gautam Bandyopadhyay; Sushil K Mahata; Daniel T O'Connor
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

Review 6.  Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity.

Authors:  Gautam K Bandyopadhyay; Sushil K Mahata
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-08       Impact factor: 5.555

7.  Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus.

Authors:  Zakir Hossain; Guru R Valicherla; Anand P Gupta; Anees A Syed; Mohammed Riyazuddin; Sharat Chandra; Mohammad I Siddiqi; Jiaur R Gayen
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

Review 8.  Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.

Authors:  Sushil K Mahata; Angelo Corti
Journal:  Ann N Y Acad Sci       Date:  2019-10-06       Impact factor: 5.691

9.  Differential DNA methylation profile in infants born small-for-gestational-age: association with markers of adiposity and insulin resistance from birth to age 24 months.

Authors:  Marta Diaz; Edurne Garde; Abel Lopez-Bermejo; Francis de Zegher; Lourdes Ibañez
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.